4.8 Article

Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer

Journal

ONCOGENE
Volume 32, Issue 7, Pages 849-860

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2012.112

Keywords

CEACAM 1; metastasis; microenvironment; intravital microscopy; MDSC; colorectal cancer

Funding

  1. Canadian Institutes for Health Research
  2. Canadian Cancer Society Research Institute
  3. Fonds de la Recherche en Sante du Quebec (FRSQ)
  4. McGill Integrated Cancer Research Training Program

Ask authors/readers for more resources

Liver metastasis is the predominant cause of colorectal cancer (CRC)-related mortality in developed countries. Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a cell adhesion molecule with reduced expression in early phases of CRC development and thus functions as a tumor growth inhibitor. However, CEACAM1 is upregulated in metastatic colon cancer, suggesting a bimodal role in CRC progression. To investigate the role of this protein in the host metastatic environment, Ceacam1(-/-) mice were injected intrasplenically with metastatic MC38 mouse CRC cells. A significant reduction in metastatic burden was observed in Ceacam1(-/-) compared with wild-type (WT) livers. Intravital microscopy showed decreased early survival of MC38 cells in Ceacam1(-/-) endothelial environment. Metastatic cell proliferation within the Ceacaml-i- livers was also diminished. Bone marrow-derived cell recruitment, attenuation of immune infiltrates and diminished CCL2, CCL3 and CCL5 chemokine production participated in the reduced Ceacam1(-/-) metastatic phenotype. Transplantations of WT bone marrow (BM) into Ceacam1(-/-) mice fully rescued metastatic development, whereas Ceacam1(-/-) BM transfer into WT mice showed reduced metastatic burden. Chimeric immune cell profiling revealed diminished recruitment of CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) to Ceacam1(-/-)metastatic livers and adoptive transfer of MDSCs confirmed the involvement of these immune cells in reduction of liver metastasis. CEACAM1 may represent a novel metastatic CRC target for treatment. Oncogene (2013) 32, 849-860; doi:10.1038/onc.2012.112; published online 2 April 2012

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available